Generally speaking, without the evidence of large randomized controlled clinical study, we could not conclude that GPi or CM‐Pf is an effective target for refractory GTS with psychiatric disorders, but the results of these cases series and our study demonstrated that both GPi and CM‐Pf is a promising target for DBS therapy on the tics and depression problem. This evidence concerns the gene GPI and depressive symptom measurement.